Avience Biomedicals Refiles DRHP for IPO of 16.08 Lakh Shares on NSE Emerge Platform

Mumbai, 25 July 2025: Avience Biomedicals Limited has refiled its Draft Red Herring Prospectus (DRHP) with the National Stock Exchange of India for an initial public offering (IPO) of up to 16,08,000 equity shares, marking its move to tap public markets for the first time. The equity shares are proposed to be listed on the NSE’s SME platform, NSE Emerge, and the issue consists entirely of a fresh offer of shares with a face value of ₹10 each.

Fresh Equity Issue of 16.08 Lakh Shares Planned for NSE Listing

As per the DRHP dated 23 July 2025, the IPO will comprise 16,08,000 fresh equity shares, with 80,400 shares reserved for the market maker and the net public issue accounting for 15,27,600 shares. The price band, offer value, and issue dates will be determined through the book-building process, in consultation with the Book Running Lead Manager, Fintellectual Corporate Advisors Private Limited. Skyline Financial Services will serve as the registrar, while Asnani Stock Broker has been appointed the market maker.

IPO Proceeds Aimed at Expanding Manufacturing and Strengthening Operations

The company has proposed to deploy the net proceeds from the IPO towards capital expenditure, working capital, and general corporate purposes. The key components include:

• ₹1,687.85 lakh for setting up a new manufacturing unit at YEIDA, Uttar Pradesh
• ₹1,100.00 lakh allocated to working capital requirements
• Remaining funds earmarked for general corporate purposes

Avience Biomedicals has already secured land from Yamuna Expressway Industrial Development Authority (YEIDA) in Sector 28, Gautam Buddha Nagar. The new facility will boost production capacity, particularly for diagnostic devices and IVD products, supporting the company’s planned operational scale-up.

Revenue More Than Doubled in FY25, Profit Surges Over 2.5 Times

The company has demonstrated impressive financial growth over the last three financial years. In FY25 (Provisional), Avience Biomedicals reported revenue from operations of ₹2,888.95 lakh, up from ₹1,625.51 lakh in FY24 and ₹1,092.06 lakh in FY23. Profit After Tax grew significantly from ₹78.26 lakh in FY23 to ₹199.43 lakh in FY24, and further to ₹519.40 lakh in FY25. The company’s net worth also improved sharply to ₹2,059.87 lakh in FY25, compared to ₹607.03 lakh in FY24 and ₹407.60 lakh in FY23. This financial performance reflects both higher manufacturing volumes and expanded trading activity in medical diagnostics.

Promoter Holding to Reduce Post-Issue But Core Stake Remains Locked

At the time of filing, the company’s promoters held 92.77% of the pre-issue equity. After the IPO, their combined holding will come down to 66.37%, subject to allotment. A total of 11,28,600 shares will be locked in for three years under SEBI ICDR Regulation 236. The break-up is as follows:

• Dharam Deo Choudhary: Pre-issue 50.57%, post-issue 36.15%, locked-in 6,27,000 shares
• Ram Nagina Choudhary: Pre-issue 20.90%, post-issue 14.94%, locked-in 2,50,800 shares
• Janardan Pal: Pre-issue 10.43%, post-issue 7.45%, locked-in 1,25,400 shares
• Deepa Choudhary: Pre-issue 10.88%, post-issue 7.77%, locked-in 1,25,400 shares

Avience Biomedicals Eyes Growth With First Public Market Entry

Established in December 2019, Avience Biomedicals Limited is engaged in the manufacture and trade of in-vitro diagnostic kits, biochemistry reagents, serology products, and medical devices. The company holds certifications including ISO 13485 and GMP, and serves hospitals, labs, and diagnostic providers across India, along with select international markets.

The upcoming IPO marks the company’s debut in the public equity space. The listing on NSE Emerge is expected to support its infrastructure expansion and bolster working capital, paving the way for broader product reach and increased production efficiency. Final IPO details—price band, valuation, and bidding dates-will be disclosed in the red herring prospectus post regulatory approvals.

REF: https://nsearchives.nseindia.com/emerge/corporates/content/trampariya_25072025120653_DRHP_Avience.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations